CHAPTER ONE

THE DRUG DEVELOPMENT PIPELINE

» Drugs in Worldwide Clinical Development
» New Drug Approvals
» Distribution of Global Drug Pipeline by Research Phase
» Worldwide Active R&D Projects in Development
» Distribution of Active Projects in Clinical Phases Only
» Distribution of Global Pipeline by Molecule Type
» Number of Companies with Active Clinical Projects Worldwide
» Top Five Largest Pharmaceutical Company Pipelines
» Most Active Clinical Pipelines
» Drugs in Preclinical Testing
» New Clinical Trials Started
» Worldwide Clinical Trial Initiations
» Worldwide Clinical Trials Volume
» Percent of Clinical Trials Initiated Outside the US
» Distribution of Active Clinical Trials
» Active Phase I Clinical Trials Worldwide
» Active Phase II Clinical Trials Worldwide
» Active Phase III Clinical Trials Worldwide
» Active Phase IV Clinical Trials Worldwide
» Distribution of Global R&D Projects by Therapeutic Area
» Drugs in Clinical Development by Therapeutic Area
» Top Five Most Active Therapeutic Areas in Clinical Testing
» Therapeutic Area Growth
» Global Compounds in R&D by Therapeutic Area: Top Five
» Global Compounds in R&D by Therapeutic Area: Next Five
» Worldwide R&D Pipeline by Therapeutic Area
» Worldwide R&D Pipeline by Therapeutic Area
» Worldwide R&D Pipeline by Therapeutic Area
» Worldwide R&D Pipeline by Therapeutic Area
» Worldwide R&D Pipeline by Therapeutic Area
» Projects in Development by Therapeutic Area
» Projects in Development by Therapeutic Area
» Projects in Development by Therapeutic Area
» Projects in Development by Therapeutic Area
» Oncology Drugs in the R&D Pipeline
» Number of Vaccine Drugs in Development
» An Expanding Vaccine Pipeline
» Primarily Phase I and II Growth in the Vaccines Development Pipeline
» First-in-Class Medicines in Development
» Drug Approvals for Rare Diseases
» Need for New Treatments for Alzheimer’s Disease
» Need for Treatments: Parkinson’s Disease
» Top Five Fastest Growing Therapeutic Areas by Prescription Drug Sales
CHAPTER TWO
DRUG DEVELOPMENT PERFORMANCE

» Cycle Time
» Drug Development Duration
» Clinical Approval Times for Drugs and Biopharmaceuticals
» Clinical and Approval Times
» Cycle Time Acceleration Targets
» Success Rates
» Phase Transition Probabilities for All Drugs
» Success Rate Variation by Molecule Size
» NCE Approval Success Rates by Therapeutic Class
» Success Rates by Therapeutic Area and Phase

» Success Rates in Oncology
» Incidence of Project Cancellations
» Estimated Value of Cancellations
» Traditional Clinical Development Scope, Purpose and Duration
» Traditional Development Duration
» Average Cycle Time from Pre-study Visit to Site Initiation
» Are Global Trials Really Faster?
» Total Approval Phase for Drugs with NDAs or BLAs Submitted FY1996-2006
» Total Approval Phase for Drugs with NDAs or BLAs Submitted FY1996-2006
CHAPTER THREE
DRUG DEVELOPMENT ECONOMICS

» Global R&D Spending
» R&D Spending
» Biopharmaceutical Companies Invest in R&D
» Annual Growth in R&D Spending
» Benchmark R&D Spend as a Percentage of Sales
» R&D Spending as a Percent of Sales by Sector
» Estimated Worldwide R&D Spending as a Percent of Sales
» Global R&D Spending and Annual Growth
» Global R&D Spending by Clinical Trial Phase
» R&D Spending by Phase
» Direct and Capitalized Cost of Developing a Single Drug
» Total Global Spending on Clinical Development
» Clinical Services Outsourcing
» Reported Percentage of Annual R&D Budget Spent on Outsourcing
» Growth in Global Phase I-III Clinical Trial Grant Spending
» Total Spending on Clinical Trial Grants

» Total Clinical Trial Grant Spending
» Clinical Trial Grant Sources for Academic Centers
» Industry Spending on Clinical Trial Grants by Phase (2008)
» Mean Cost Per Patient by Phase
» Annual Growth in Per Patient Cost
» Mean Cost Per Patient by Therapeutic Area Across Phases I-III
» Screen Failure Costs as a Percentage of Total Cost per Patient
» Mean Per Patient Costs 2008-2011 Relative to North American Rates
» Average Number of Patient Payments by Annual Recruitment Volume
» Reported Time Required for Sites to Process One Payment
» Reported Number of Administrative Steps per Patient Payment
» Mean Patient Reimbursement Per Visit
» Mean Patient Reimbursement Per Visit by Therapeutic Area Across Phases II & III
» Industry Spend on KOLs
» Average Hourly Rates
CHAPTER FOUR

CLINICAL RESEARCH PARTNERS

» Contract Clinical Outsourcing
» Total Global Market for Contract R&D Services
» Clinical Trial Laboratory Services Market Size
» Global Market for Contract Preclinical and Clinical Services
» Clinical Services Outsourcing
» The Integral Role of CRO Partners: Worldwide R&D Capacity
» Percentage of Budget Dollars Spent on Outsourcing
» Pharma Industry Job Cuts: U.S.
» Top Pharma Staffing Changes
» Pharma Executive Compensation
» Top CROs by Worldwide Employee Size
» Incidence of Site Management Responsibilities Outsourced to CROs
» Site Management Responsibilities Outsourced by Company Size
» Site Ratings of Sponsor and CROs Relationship Attributes
» Site Ratings of Sponsor and CRO Study Conduct Support Attributes
» Number of Sponsor FTEs Assigned per 100 Dedicated CRO FTEs
» Major CRO Proclivity to Acquire Companies
» Most Active Major CROs
» Profile--inVentiv Health
» Comparing Major CRO M&A Activity Over Two Time Periods

» Volunteer Consent Rates When Asked by Physician/PI to Participate
» Screen Failure Costs as a Percentage of Total Cost per Patient
» Incidence of Pre-study Visits Performed by Sponsors
» Impact of Pre-study Visits
» Industry Spend on KOLs
» Average Hourly Rates
» Average Number of Pages per Investigator Brochure
» Parexel Annual Revenue
» Parexel Annual Revenue Growth Rates
» Distribution of Fiscal 2012 Revenue
» Evolving Parexel Scale and Infrastructure
» Principal Investigator Disparities
» Sponsor Reports of Minority Investigator Performance Compared to that of White Investigators
» Comparing Site Ratings of Overall Relationship Quality with CROs
» Distribution of Contract Clinical Services Market Segments
» The Global Investigative Site Landscape
» 30 Years of Expanding Services and Outsourcing Models
» High Global Demand for CRO Services
» Leading CROs
CHAPTER FOUR

CLINICAL RESEARCH PARTNERS

» Proportion of Top 30 Pharma Companies in at least One FSP/Multi-FSP/Integrated Alliance
» Expected Impact from Strategic Outsourcing Relationships
» Sponsor Participation in Open Innovation Initiatives
» CHORUS Model Estimated Time and Cost Improvements
» Profile of the Structural Genomics Consortium
» Investigative Site Landscape
» Active Unique Investigators Filing Form 1572s World Wide
» Proportion of Novice Investigators Conducting Clinical Trials
» Global Distribution of 1572 Filings
» Distribution of Industry-Funded Clinical Trials in the U.S.
» Global Market Share of Active Clinical Trials by Investigative Site Setting
» Comparing Network Size
» Geographic Focus and Scope
» Largest Site Management Organizations in 2000
» Number of Clinical Grants Awarded
» Distribution of Annual Study Volume per Investigator
» Top Investigative Site Operating Concerns
» Economic Outlook by Years of Site Experience Conducting Clinical Trials
» Rising Scope and Declining Size of Clinical Trials
» Site Reported Cancellations
» Site Reported Recovery of Start-Up Costs Associated with Cancellations
» Global Investigative Site Staffing
» Total FTE Employees per Investigative Site
» Mean Number of Employees by Staff Type (Full and Part Time)
» Mean Number of Employees by Staff Type by Region (Full and Part Time)
» Global Investigative Site Mean Revenue and Profitability
» Investigative Site Expenses and Profit
» Type of Accounting Method Used by Investigative Sites
» Wide Differences in Site Payable and Receivable Cycles
» Percentage of Clinical Research Revenue Owed That was Written off as Bad Debt in 2011
» The Increasing Proportion of Low Volume Investigators
» Investigator Turnover Rates by Region
» Investigator Dropout Rates
» Investigator Continuity and Decay Rates
» Rolling Change in Total Active Unique Investigators Filing Form 1572s
» Investigative Site Outlook 2011
» Investigator Dropout Rates
» Global Investigative Site Mean Revenue and Profitability
» Distribution of Total Investigative Site Expenses
CHAPTER FOUR

CLINICAL RESEARCH PARTNERS

» Perceived Economic Conditions
» Profit Expectations for 2012
» Sponsor Payment Promptness
» Revenue and Profitability by Investigative Site Size
  » Profile: Small Sites
  » Profile: Mid-sized Sites
  » Profile: Large Sites
» Growth in Clinical Grant Revenue by Investigative Site Type
» The Investigative Site Landscape in Western Europe
» Allocation of Clinical Trial Grant Expenses
» Investigative Site Personnel Size
» Distribution of Investigators by Site Type
» Perception of 2012 Economic Conditions Compared to 2011
» Average Clinical Trial Grant Size
» Traditional and Non-Traditional Recruitment Tactics Used
» Typical Site Enrollment Performance
» Enrollment Achievement by All Sites in a Given Region
» Top Factors Most Often Causing Clinical Trial Delays
» Clinical Research Coordinators
» Years in Current Position Comparison to Previous Years
» Years Clinical Research Experience Comparison to Previous Years
» Years in Current Position by Years of Clinical Research Experience
» Clinical Research Coordinator Workload
» Clinical Research Coordinator Salaries
» Distribution of Full-Time Clinical Research Coordinators
» Distribution of Part-Time Clinical Research Coordinators
» Summary of Significant Differences For-Profit vs Not-for-Profit
» Highest Level of Education Completed
» Highest Level of Education Completed
» Certification
» Certification - Organization
» Year Certified
» Ongoing Training
» Primary Training Sources
» PI and CRC Ratings of GCP Training
» Primary Payer of CE Credits
» Distribution of Full-Time Clinical Research Coordinators
» Distribution of Part-Time Clinical Research Coordinators
» Study Coordinators: Number of Years in Current Position
» Years in Clinical Research
» Study Coordinator Experience
CHAPTER FOUR

CLINICAL RESEARCH PARTNERS

» Length of Employment at Current Site
» Study Coordinator Employment Continuity
» Annual Full-Time CRC Turnover Rate
» Position CRCs Most Aspire to Advance Into
» Study Coordinator Base Salary
» Supplemental Income
» Average Supplemental Income
» Base Salary Increase Within Past Year
» Average % Base Salary Increase
» Number of Studies Personally Overseeing
» Number of Patients Personally Overseeing
» Number of Hours Worked Per Week
» Responsibility Distribution
» Activity Distribution
» Change in Level of Responsibilities Over Past Year
» Change in CRC Responsibilities Over Past Year
» Perception: Is Salary Commensurate with Additional Workload?
» Most Common Obstacles in Completing Tasks
» Top Perceived CRC Career Benefits
» Top Perceived CRC Career Challenges
» Study Coordinator Distribution by Site Type
» PhRMA Personnel

» Various Clinical Trial Activities
» CRA Time Allocation by Region
» Regional Variation in CRA Quality-of-Life Assessments
» Patients/Study Volunteers
» Average Number of Volunteers Enrolled per Clinical Trial
» Factors Contributing Most to Delays in Enrolling the First Patient
» Study Start-Up Cycle Time by Site Type
» Study Start-Up Cycle Time by Region
» Study Volunteer Attrition Rates
» Reasons Patients Seek Clinical Trials Information
» Methods Used to Search for Clinical Trials
» Internet Resources Most Used by Patients for Clinical Trials Information
» Preferred Method to Contact Research Centers to Participate in a Clinical Trial
» Participation in a Clinical Trial
» Consider Participating in a Clinical Trial Again
» Resources Used to Learn About Participating in Clinical Trials
» Did You Seek Assistance in Deciding to Participate in a Clinical Trial
» Individual Involved in the Decision-Making Process
» Evaluation of the Informed Consent Process Before the Start of the Clinical Trial
CHAPTER FOUR

CLINICAL RESEARCH PARTNERS

» Did You Feel that You Understood the Benefits and Risks of Participating in a Clinical Trial?
» Volunteer Ratings of Research Staff Who Conducted the Clinical Trial
» Study Participant Concerns
» Preference for Follow-up on Clinical Trials
» How Many Studies Have You Participated In?
» Most Frequent Illness Addressed?
» How Did You First Contact the Study Center?
» How Much Time Did it Take Before the Study Staff First Contacted You?
» How Long Was The Study?
» How Many Visits Were Required for the Study?
» How Aware Were You About Clinical Trials as a Treatment Option Prior to Learning About this Study?
» Factors Impacting Volunteer Willingness to Participate
» Factors Reducing Volunteer Willingness to Participate
» Who Helped You Make the Decision to Participate?
» Study Participation Concerns
» How Knowledgeable Was Your Physician About Where You Could Find More Information About Active Clinical Trials?
» Were You Compensated for Your Participation in the Study?
» Did You Receive Any Support that Assisted You in Participating?

» Type of Support Received?
» Whom Did You Initially Meet With On Your First Visit?
» Did You Receive an Informed Consent Form Before Beginning the Study?
» Did You Read the Informed Consent Form?
» Who Reviewed the Informed Consent Form with You?
» How Well Did You Understand the Informed Consent Form?
» I Understood That I May Receive a Placebo (Sugar Pill) Instead of the Investigational Medicine
» Understanding Study Expectations
» Understanding Study Expectations
» Understanding Study Expectations
» Was Medical Care Helpful During the Trial?
» Dropping Out of the Study
» Reasons for Dropping Out
» How Would You Rate the Overall Quality of Care Received During the Study?
» Would You Participate in a Clinical Trial Again?
» Would You Recommend that a Member of Your Family or Friend Participate in a Clinical Study?
» Distribution of Time Spent Blogging Per Week
» 2011 Internet Usage Statistics
» Blogger Demographics
CHAPTER FOUR

CLINICAL RESEARCH PARTNERS

» Clinical Trial Information Seekers: Main Motivation
» Health Seekers’ Areas of Interest
» Profile of Six Million Clinical Trial Information Seekers
» Study Volunteer Disparities in Clinical Research
» Patient Perceptions of Clinical Research Safety by Race and Ethnicity
» Patient Concentration by Physician Race and Ethnicity
» Patient-reported Top Sources of Clinical Trial Information
» Growth of Routine Usage of Social Networks by Adult Internet Users
» Patient Organizations Funding Clinical Research
» Distribution of Medical Apps on Mobile Devices
CHAPTER FIVE

CLINICAL RESEARCH PRACTICES

» Protocol Design
» Protocol Complexity and Execution Burden
» Complexity and Work Burden by Phase
» Impact on Clinical Trial Performance
» Protocol Complexity Impact on Cycle Time
» Growth in Protocol Complexity and Work Burden by Phase
» How Important is Protocol Design to Your Decision to Participate in a Clinical Trial?
» Phase II and III Study Execution 2012
» Distribution of Protocol Procedures
» The Impact of Complexity on Study Performance
» Amendment Prevalence
» Amendment Prevalence by TA
» Avoiding Amendments
» Amendment Timing
» Procedure Support of Endpoints
» Distribution of Procedures by CSR/Analysis Plan Classifications
» Distribution of, and Total, Direct Cost per Classified Protocol Procedures
» Distribution and Cost of Procedures by Endpoint Classification and Phase
» Relationship Management and Effectiveness

» Average 2011 Rating of Relationship Quality for a Typical Sponsor
» Sponsor Rating of Overall Relationship Quality
» Regional Comparison--Average Sponsor Ratings
» Average Sponsor Ratings by Site Type
» Average Sponsor Ratings by Years of Experience
» Company Ratings of Relationship Quality
» Company Ratings of Relationship Quality
» Frequency of Attributes in Top 3
» Essential Attributes to Study Success
» The Top Sponsors by Essential Attributes
» Evaluating Sponsor Performance
» Evaluating Sponsor Performance
» Comparing Performance Quality to Category Importance
» Comparing Attribute Importance to Sponsor Performance--Gaps
» Quality of Staff Professionalism
» Quality of Workstyle
» Quality of General Project Management
» Quality of Study Initiation Process
» Quality of Ongoing Study Conduct
» Quality of Grant Payment Process
» Average 2011 Relationship Quality Rating for the Typical CRO
CHAPTER FIVE

CLINICAL RESEARCH PRACTICES

» Benchmark Proportion of Sites Rating CRO Relationship Quality
» Regional Comparison of Average CRO Ratings
» Average CRO Ratings by Site Type
» Average CRO Ratings by Years of Experience
» The Top Rated CROs
» Site Ratings by Experience and Setting
» Comparing Performance Quality to Category Importance
» Comparing Attribute Importance to CRO Performance--Gaps
» Quality of Staff Professionalism
» Quality of Workstyle
» Quality of General Project Management
» Quality of Study Initiation Process
» Quality of Ongoing Study Conduct
» Quality of Grant Payment Process
» Sponsors Engaging More Sites to Each Enroll Fewer Patients
» Investigative Site Enrollment Performance CL0513/CL0513_060.png
» Number of Countries in which Sponsors are Placing Clinical Trials
» Key Performance Metrics For Investigative Sites by Region
» Trends in Oncology Trial Protocol Complexity
» Days Spent On Site Each Month by Study Monitors
» Prevalence of Academic Research Faculty Relationships with Industry

» Comparing Site Ratings of Overall Relationship Quality with CROs
» Sponsors Receiving Top Relationship Ratings from their Sites
» Site Assessment of Relationship Attribute Importance and of Sponsor Ability to Provide Them
» Gaps Between Relationship Attribute Importance and "Excellence" Ratings of Sponsor Ability to Provide Them
» Individual Relationship Attributes Rated the Highest
» Individual Relationship Attributes Rated the Lowest
» Sites Rate Each Company's Overall Reputation as a Sponsor of Clinical Research
» Patient Recruitment
» Distribution of Global Development Spending, Trial Volume and Patient Enrollment
» Probability of Successful Investigative Site Performance
» Preferred Patient Recruitment Methods
» Aggregate Patient Recruitment Success Rates
» Reasons Patients Seek Online Clinical Trials Information
» Individuals Who Would Most Influence Your Decision to Participate
» Top Site Perceived Factors Contributing to Faster Cycle Times
» Factors Contributing Most to Delays in Enrolling the First Patient
» Factors That Most Often Cause Delays
» Factors That Could Best Prevent Future Delays
CHAPTER FIVE

CLINICAL RESEARCH PRACTICES

» Enrollment Delays
» Enrollment Delays by Region
» Percent of Sites Extending Patient Enrollment Period
» Development Technology Solutions
» EDC Solutions
» Estimated EHR Market Growth
» Hospital System Adoption of EHRs
» Practicing Physician Adoption of EHR Systems
» Barriers to Hospital System Adoption of EHRs
» Top Barriers to Practicing Physician Adoption of EHRs
» eCT Systems at Investigative Sites
» Top Reasons for Delay in Improving eCT Compatibility at Sites

» Preferred EDC Training Method
» Top Suggestions for Ways to Improve Sponsor/CRO Help Desk Support
» Proportion of Companies Performing 100% Source Verification
» CRA-reported Days per Month Spent Visiting Sites by Region
» Factors Determining the Frequency of On-site Monitoring Visits
» Total CRA-reported Workload per Month
» Growth of Routine Usage of Social Networks by Adult Internet Users
» Distribution of Medical Apps on Mobile Devices
» Technology Use Among IRBs
» Top 10 Pharma Companies On Twitter
CHAPTER SEVEN

DRUG DEVELOPMENT REGULATION

» Drug Development Regulation
» IND and NDA Submissions and Approvals
» Number of IND Submissions
» Number of INDs Submitted Each Quarter 2010-2011YTD
» Total NDA Submissions and Approvals
» Original NDA/BLA Submissions
» NDA Submissions by Filing Status
» BLA Submissions by Filing Status
» NDAs Approved in First Review Cycle
» NMEs/NBEs First-Cycle Review Outcomes
» NME Submissions by Filing Status
» Number of NDAs and NMEs Approved
» Approved NDAs and NMEs Receiving Priority Designations
» NMEs Approved with Postmarketing Requirements and/or REMs
» NME/BLA Approvals
» NDA Approvals
» New Biologic Approvals
» FDA Orphan Drug Approvals
» FDA Orphan Drug Designations
» FDA Orphan Drug Approvals and Designations
» Regulatory Review and Approval Cycle Time
» Cycle Time in Years from IND Approval to NDA Approval

» Mean NME Approvals Times
» Median Approval Times for Biotech Drugs and Biologics
» Mean EMA Processing Time for Human Medicinal Products
» FDA Inspection Results
» FDA, CDER Inspections of Sponsors and CROs
» Complaints Filed Against Investigators
» Complaints Filed Against Investigative Sites as a Percentage of Active INDs
» CDER Inspections of Clinical Investigators
» Investigator Deficiencies: Final Classification of OAI
» Bioresearch Monitoring Inspections Overseen by FDAs CDER
» Site Audit Preparedness
» Warning Letters Issued to Principal Investigators
» FDA Inspection Results
» Investigator Disqualifications
» Estimated Time to Enroll FDA-Regulated Phase III Cancer Studies
» Global Distribution of FDA-Regulated Clinical Trials
» Rising Proportion of New and Inexperienced Investigators
» Complaints Received, and Inspections Performed, by the FDA for Noncompliance and Fraud
» Distribution of Complaints against Investigators for Noncompliance and Fraud
CHAPTER SEVEN

DRUG DEVELOPMENT REGULATION

» Volume of Physician-filed INDs
» Investigator-Initiated Trials as a Proportion of Active INDs
» Tracking IND Submission Sources and Growth Rates
» Number of Commercial IRBs in the U.S.
» Annual Reported Change in Workload and Resources Required

» Incidence and Level of Commercial IRB Use by Institutional IRBs
» Technology Use Among IRBs
» Evaluable Patients per NDA
» Average Number of Pages per Investigator Brochure